Condition
Tirzepatide
Total Trials
5
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
60%
3 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
5Total
Not Applicable (2)
P 3 (1)
P 4 (2)
Trial Status
Not Yet Recruiting3
Recruiting2
Clinical Trials (5)
Showing 5 of 5 trials
NCT07811895Not ApplicableNot Yet RecruitingPrimary
Dual GIP/GLP-1 Receptor Agonist in Obese Women Before Frozen Embryo Transfer
NCT07387796Not ApplicableRecruiting
Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation
NCT07738276Phase 3Not Yet Recruiting
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity
NCT07630454Phase 4Not Yet Recruiting
Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF
NCT07423247Phase 4RecruitingPrimary
Tirzepatide (Spartina) in Obese Kidney Transplant Recipients
Showing all 5 trials